Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"$445.0 million","upfrontCash":"$210.0 million","newsHeadline":"Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Cholic Acid

    Menu

    Cholic Acid

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Travere Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

              Details:

              Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.

              Lead Product(s): Cholic Acid

              Therapeutic Area: Genetic Disease Product Name: Cholbam

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mirum Pharmaceuticals

              Deal Size: $445.0 million Upfront Cash: $210.0 million

              Deal Type: Divestment July 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Cholic Acid
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Close
              4
              Post Enquiry
              POST ENQUIRY